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INTRODUCTION 
 
Worldwide, Primary cause of death in HIV patients is 
Tuberculosis. Active  tuberculosis seen in HIV positive patients than HIV 
negative patients by 100 times. Active tuberculosis is associated with 
high levels of plasma HIV RNA and reduced with anti tuberculosis 
treatment.HIV and TB co-infection itself can accelerate the course of 
other disease. The treatment of patients co-infected with HIV and TB 
requires careful management. Potential interactions between anti-
tuberculosis and antiretroviral drugs may result in sub-therapeutic levels 
or toxicity. Relapse of tuberculosis and reactivation of TB is more 
common in HIV positive Individuals. This high burden of 
HIV/Tuberculosis co-infection is a concern as there is a higher risk of 
death for patients who are co-infected with HIV and Tuberculosis than 
those who either are only HIV-positive or only infected with TB . 
It is necessary to understand the underlying epidemiology involved 
in transmission and disease progression to comprehend the synergy 
between the HIV and Tuberculosis and how one is fuelled by the other. 
The Provision of ART to TB patients with HIV is seen as a very 
important in addition to DOTS in preventing premature death and 
achieving the Millennium Development goals. Optimal time to initiate 
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ABSTRACT 
 
BACKGROUND: 
 
For antiretroviral therapy (ART) naive human immunodeficiency virus 
 
 (HIV) infected adults suffering from tuberculosis (TB), there is uncertainty about  
 
the optimal time to initiate highly active antiretroviral therapy (HAART) after  
 
startingantituberculosis treatment (ATT), in order  to minimize mortality, HIV  
 
disease progression, and adverse events.The ART is started 2-8 weeks  
 
afterinitiation ATT IN patients with HIV-TB to minimise the chances of immune  
 
reconstitution inflammatory syndrome. 
 
 
AIMS AND OBJECTIVES 
 To compare the incidence of IRIS, adverse effects, outcome  of tuberculosis 
,CD4 cell count, progression of HIV in early antiretroviral therapy and 
delayed antiretroviral therapy group with HIV TB co-infection on ATT. 
 To decide optimal time to initiate ART in HIV TB co-infection on ATT 
  
MATERIALS AND METHODS 
 
The study will be conducted among patients admitted to the in patient 
 
wards in the Department of Internal Medicine and those attending as out patients  
 
in a Tertiary Medical College Hospital who have been diagnosed as a case of HIV  
 
and Tuberculosis co infection. 
 
 
 
TYPE OF STUDY: 
 
Unicentric prospective study 
 
 
EXPECTED  RESULTS: 
 
Early initiation of HAART for patients with HIV and TB significantly 
 
decreases incidence of HIV disease progression and has good tolerability. 
 
 
USEFULNESS OF STUDY: 
 
Worldwide approximately  one third of all HIV  related deaths are  
 
associated with TB,and  TB is the primary cause of death for 10-15%  of patients  
 
with HIVinfection.Patients with HIVINFECTION ARE MORE LIKELY TO HAVE ACTIVE TB 
 
,BY A FACTOR OF 100 WHEN COMPARED WITH AN HIV NEGATIVE POPULATION .UNTREATED  
 
TB CAN ACCELERATE  THE COURSE OF HIV INFECTION.  
 
 
 
 
 
In this  study early ART group  
 
(within2 to 8 weeks after initiation of  ATT) and late ART group (after 8 weeksof  
 
initiation of ATT) is compared for the incidence of IRIS, adverse effects, outcome  
 
of tuberculosis ,CD4 cell count ,progression of HIV. 
 
 
 This study  will help us determine the optimal time to initiate ART in HIV-TB  
cases.   
 
 
 
 
Keywords 
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HIV- TB Co-infection   
  
ART in HIV Tuberculosis co-infected individuals on ATT is still 
controversial. ART is usually started 2-8 weeks after initiation of ATT in 
patients with HIV-TB to minimise the chances of immune reconstitution 
inflammatory syndrome (IRIS). 
In this  study early ART group  (within 2 to 8 weeks after initiation 
of ATT) and late ART group (after 8 weeks of  initiation of ATT) is 
compared for the incidence of IRIS, adverse effects ,CD4 cell count 
,progression of HIV, outcome of Tuberculosis. This study will help us 
determine the optimal time to initiate ART in HIV-TB  cases. 
  
  
 
 
 
 
AIMS AND 
OBJECTIVES 
  
  
 
AIMS AND OBJECTIVES 
 To compare the incidence of IRIS, adverse effects, outcome  of 
tuberculosis ,CD4 cell count, progression of HIV in early 
antiretroviral therapy and delayed antiretroviral therapy group with 
HIV TB co-infection on ATT. 
 To decide optimal time to initiate ART in HIV TB co-infection on 
ATT 
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REVIEW OF LITERATURE 
HISTORY AND EPIDEMIOLOGY OF HIV 
“33 years after the first reported cases of the acquired 
immunodeficiency syndrome(AIDS) and 30 years after the discovery of 
the etiologic agent, effective control of the HIV and AIDS pandemic 
remains elusive” .In June 1981, First CDC (centre of disease control)  
announced a new syndrome later coined “Acquired Immune Deficiency 
syndrome”[1, 2]. By 1983,the etiological agent for AIDS was identified 
and later named as human immunodeficiency virus (HIV) [3]. HIV 
disease pathogenesis is complex and multifactorial [4, 5].After HIV 
infection ,it enters into the lymphoid organs by viral replication [6, 7]. An 
immune mechanism usually inhibits viral replication within weeks, but 
the virus spurts from  it, producing a chronic persistent infection leading 
to advanced clinical disease [8, 9].  
A subspecies of chimpanzees native to  Africa had been identified 
as the  source of the virus. Scientists believe that simian 
immunodeficiency virus (called SIV) was transmitted to humans and 
mutated into HIV [10-12].There are 2 types of HIV:HIV-1 and HIV-2. 
Both types are transmitted by sexual contact, through blood, and from 
mother to child (more so for HIV-1 than HIV-2), and they appear to cause 
clinically indistinguishable AIDS. However, it seems that HIV-2have 
  
incubation period less than HIV-1,chance of transmission is less than 
HIV-1 
 
Worldwide, the predominant virus is HIV-1, and HIV-2 type is 
found mainly in West Africa and is rarely found elsewhere. The strains of 
HIV-1 can be classified into four groups:  
 
1. "major" group M, 
2. "outlier" group O  
3. two new groups, N and P.  
 
These groups are representing introductions of SIV to humans. M 
group is the most common cause of HIV in world. M group divided into 9 
subtypes. These are8 subtypes A-K except E & I [13-15]. Two virus 
subtypes can meet and mix their genetic material to create a new hybrid 
virus in the cell of an infected person  [16]. "circulating recombinant 
forms"  is the virus that infect more than one person [17]. Several studies   
suggested that HIV-1 subtypes  show distinct ecological distributions[18-
23][24, 25]. Worldwide it has been shown that 48% of infections are 
caused by subtype C, 12% by subtype A, 11% by subtype B, 5% by 
subtype G, 2 % by subtype D and 22% recombinants [26].In 2010  ,34 
  
million were with HIV and 2.7 million  were  new infections [27]. 
Worldwide decreasing new HIV infected individuals.  
 
The reason for decreasing in trend are 
1.HIV natural course 
2. Antiretroviral therapy 
3.behavioural change [28] 
 
EPIDEMIOLOGY OF HIV IN INDIA [29] 
 
2.4 million in India living with HIV next to South Africa.             
Men more affected than women0.3% of India‟s population living with 
HIV Prevalence in ANC  is 0.6%Maharasthra,, Tamil Nadu, ,AP, 
,Karnataka, Manipur and Nagaland having prevalence >1% in pregnant 
women 
  
  
 
SUMMARY OF AIDS EPIDEMIC IN INDIA [29] 
 
 
 
 
 
  
NUMBER OF 
 
PEOPLE LIVING 
 
WITH HIV 
TOTAL 
2.4 MILLION 
(1.9-3.0MILLION) 
MALE 61% 
FEMALE 35.5% 
CHILDREN 3.5% 
PREVALENCE 
AMONG ADULTS 
OVERALL 0.31% 
MALE 0.44% 
FEMALE 0.23% 
  
 
 
 
FIGURE 1: 
STATE-WISE ESTIMATED ADULT HIV PREVALENCE, 
2006-2007. [29] 
 
 
 
  
 
PATHOGENESIS OF HIV INFECTION [30,31] 
HIV enters    and        binds to      DC     which carry the virus to T 
helper  or CD4 cells in lymphoid tissue establishing the infection. Human 
immunodeficiency virus   targets and binds to the macrophages and CD 4 
cells . After entry into CD4 cells it replicates within the cell. More helper 
cell  are infected secondary to lysis and release  new virus. During the 
course massive  numbers of virus (>1billion/day) are released. The 
destruction of CD 4 cell count is the primary effect of HIV infection. 
CD4 cell destruction occurs in HIV infection, due to various mechanisms 
even in non HIV infected cell. Apoptosis  and syncytium formed by 
membrane fusion of adjacent cells are the main mechanisms by which 
HIV destroys CD4 cells. This syncytium is short survived  and seen in 
late stages of HIV infection. Virus and cytotoxic T cells destroy CD4 cell.  
 
CD4 cell count decreases progressively during the course of HIV 
infection .Reverse transcriptase is used in conversion of viral RNA to 
DNA. By using integrase enzyme it is incorporated to human DNA. After 
replication using protease enzyme viral genomes are assembled. 
  
  
 
HIV STRUCTURE 
Human immune deficiency virus is an enveloped, positive stranded 
RNA virus, that measures 120 nm in diameter and consists of a lipid 
bilayer with uniformly arranged 72 spikes or knobs  of glycoprotein – 
gp120 and gp 41 (HIV-1)/gp 36 (HIV-2). The virion gp120 located on the 
virus surface contains the binding site for cellular receptor(s). The two 
plus stranded RNA molecules are embedded in a protein capsid (p24) 
together with certain viral enzymes (viral RNA-dependent DNA 
polymerase (Pol, also called the reverse transcriptase, RT (p66, p51) and 
nucleocapsid proteins (p9, p7). The capsid (p24) is surrounded by a 
matrix layer (p17) that in turn is enclosed in lipid bi-layer, the envelope. 
  
  
 
 
 
 
 
 
 
FIG 2:    HIV VIRAL GENOME 
 
 
 
  
  
1. The gag gene codes for the proteins p24, p17, p9 and p7.  
2. The pol gene codes for the reverse transcriptase (RT),the                     
protease (PR), and the integrase (IN) proteins.  
3. The envelope gene codes for the gp120 and gp41 proteins                    
which are made from a precursor gp160 
4. Tat, a transactivating protein, which along with certain cellular 
proteins, interacts with an  RNA loop structure formed in the 
3‟portion of the virus and upregulates HIV replication. 
 
The other regulatory  protein  which is needed for the synthesis of viral 
proteins: 
1. Nef(Negative factor), whose actual function remains unclear and is 
believed to down regulate viral expression. 
2. The accessory HIV viral gene products and  
3. vif, vpr, vpu/vpx appear to influence events such as assembly and 
budding, as well as infectivity involved in the production of 
infectious viruses. 
 
 
 
 
 
  
 
 
 
FIG 3: DETRUCTION OF THE IMMUNE SYSTEM [30] 
 
 
 
 
  
 
 
 
 
FIG 4: DESTRUCTION OF CD4 CELLS [31]. 
 
  
  
TRANSMISSION OF VIRUS 
The primary routes of HIV transmission are through sexual 
intercourse, vertically from mother to infant during pregnancy or early 
infancy, per cutaneous exposure and exposure to infected blood and its 
products. In children, mother to child transmission (MTCT) is the major 
route
[32]
] 
COMMON MODES OF TRANSMISSION OF HIV AND THEIR  
RELATIVE RISK
[33]
 
 
Sl. No. Types of Exposure 
Approximate chance 
of infection 
per exposure 
1 
Sexual intercourse-anal, 
vaginal, oral 0.1 - 1.0% 
2 
Blood and blood 
products transfusion > 90% 
3 
Tissue and organ donation: 
semen, cornea, 
bone marrow etc 
50 - 90% 
4 
Injections and injuries: 
shared needles in IV drug users. 
Unsterile syringes and needles. 
Accidental injury to health personnel 
0.5 - 1.0% 
5 
Mother to baby: Trans placental, 
at birth, 30% 
 
  
 
 
 
 
 
 
FIG 5:    ROUTE OF TRANSMISSION [29] 
  
  
PERIPHERAL BLOOD CD4  T LYMPHOCYTE COUNTS IN 
HEALTHY ADULT INDIANS [34] 
CD4 T cells are the primary target cells for human 
immunodeficiency virus (HIV). Hence  CD4T lymphocyte count is the 
important  key marker of immune dysfunction in  Human 
immunodeficiency virus disease progression. The measurement CD4 cell 
counts is useful to determine  the initiation of HAART, to observe  the 
efficacy of HAART and to initiate management for  opportunistic 
infections . To develop the threshold levels of CD4 T cell counts, data  
from western countries are being used in India. Race and environment 
factors play a pivotal  role in the CD4 T  cell count. So to understand 
immune dysfunction it is necessary to know ranges for the CD4cell 
counts in the study population. Flow cytometry is the gold standard for 
the estimation ofCD4+ T cell counts due to its accuracy, precision and 
reproducibility and hence it is used widely. 
The CD4  T cell count has been shown to be influenced by 
1. Sex, age, race. 
2.Time of specimen collection (diurnal rhythms) 
3.Physical and psychological stress 
4. Pregnancy 
  
5.Drug  administration (Zidovudine, Cephalosporin, Cancer 
chemotherapy, Nicotine and Steroids) 
6. Tuberculosis 
7. Viral infections, 
8.Presenceof anti-lymphocyte auto antibodies and 
procedures like splenectomy.  
 
Females tend to have higher CD4 cell counts than males; on 
contrary  females have less CD8 cell counts than males. Although in 
adults, age does not have influence on CD4 cell counts significantly, 
lower CD4 cell counts may be observed in geriatric population. Even 
under strict quality control regime, the variations in CD4  T cell counts 
measured using different equipment and following different 
methodologies can be as high as 20 percent in controlled conditions with 
adequate technical expertise. Diurnal variation (the difference in the CD4 
counts in the sample collected at different time points during 24 h period 
in the same individual) adds to this variation by as much as 20 per cent. 
The lowest level of CD4 T cell counts was seen in the morning around 
10.00 h and the highest at around 20.00 h. Hence for the sake of 
comparability of values it is recommended that the blood for CD4 T 
cell counts should always be drawn at the same time of the day in a 
given individual. 
  
CD4 T cells are also known to oscillate with vigorous physical 
activity. A study conducted in 20 healthy HIV-negative individuals 
showed significant reduction  in the CD4 T lymphocyte  count after  rest 
for 1 hour. As against absolute CD4 T cell count, CD4 per cent is 
found to be more stable with respect to time of the day, reagents, 
equipment used, gating strategies and biological factors that  
influence the CD4 counts. Though CD4 per cent is not considered a 
good predictor of HIV disease progression, it indicates whether the rise or 
drop in CD4 Tcell count is a real change or just a fluctuation. The 
reported lowest value of CD4+ T cells count varied between 304 to 500 
cells/µl and highest CD4 T cells count varied between 1000 cells/µl to as 
high as 1864 cells/µl indicating the wide difference that exists in the CD4 
. The meanCD4 counts in the North India varied from as low as 703 to 
818 cells/µl, in South India from 799 to 1048 cells/µl, in western India 
from 743 to 965 cells/µl  and 848 cells/µl in Eastern India. 
 
High risk behaviour of acquiring HIV when CD4:CD8 ratio is less 
than 0.85.However, the studies conducted in normal Indian populations 
showed variations in CD4:CD8 ratio from 0.04 to 3.5. The mean CD4: 
CD8 ratio varied between 0.94 to 1.78 in different studies. The ICMR 
multicentric study has reported a mean CD4:CD8 ratio of 1.2 from the six 
centres in different locations in India. 
  
CD4 CELL COUNTS IN HUMAN IMMUNO DEFICIENCY  
VIRUS INFECTED INDIVIDUALS IN INDIA: 
An Indian study showed that people infected with human 
immunodeficiency virus withCD4 T cell count of 200to 350 cells /µl had 
increased viral load than international AIDS  Society suggestion  and 
CD4T cell count cut off is 243 cells/µl reported in this study 
distinguished asymptomatic (CDC clinical category A) from symptomatic 
(CDC  clinical category B) individuals.  
 
In this study  deferral of ART was associated with increased  
risk of death sixty nine percent of individuals with CD4 more than 
350cells. In the light of this finding, the reference ranges might be of 
great importance in making decisions on the initiation of the ART. 
 
CLINICAL FEATURES 
The Human immunodeficiency virus infection  pandemic consists 
of many separate epidemics. Physiologically, HIV infection  more 
common in women than men by 4 times Mechanisms are 
1. Semen which is infected  remains in the cervix for longer time,  
2. Large surface area in the vagina and cervix  
  
3. The vagina is more susceptible to small tears during sexual 
contact 
4. Young women‟s cervixes are even more vulnerable, particularly 
when they first start having sex. 
Human immunodeficiency virus enters into infected cell, by using 
reverse transcriptase enzyme it forms DNA from RNA, incorporate into 
human DNA by integrase. It thus establishes a latent infection for the rest 
of  the life of the infected individual. HIV is then activated to produce 
new virions whenever the infected CD4 cell is activated. An HIV coded 
protease is active in the maturation of the virions at the cell surface. This 
viral production disturbs CD4 cell function and eventually exhausts the 
CD4 cells leading to increased immunodeficiency and increased 
vulnerability to opportunistic infections and death. The symptoms are  
differing according  to  the stage of infection. Though PLWHA tend to be  
infectious in the first few months. The first few weeks after initial 
infection, individuals may have no symptoms flu-like illness including  
1. fever 
2. headache, rash  
3. swollen lymph nodes, weight loss 
4. diarrhoea   
5. cough.  
6. tuberculosis (TB) 
7. cryptococcal meningitis 
  
and in advanced stage cancers such as lymphomas and Kaposi‟s 
sarcoma. The most advanced stage of HIV infection is AIDS. It can take 
10-15 years for an HIV-infected person to develop AIDS. 
PROGRESS AND CLINICAL STAGES OF DISEASE [29] 
Lymphocytes, MM series and DCs constitute the backbone of 
CMI. HIV affects almost all cells. The immune apparatus and function 
show the most obvious primary clinico-pathologic manifestations. Others 
which bear the primary brunt are the gastrointestinal tract (GIT) and 
CNS. 
 
PATHOGENESIS OF IMMUNODEFICIENCY  
THE VARYING PHASES OF IMMUNE REACTION 
INCUBATION PERIOD 
After transmucosal (and also parenteral) transmission, HIV reaches 
and establishes in T-cell areas of lymph nodes. Mucosal and nodal 
changes and early viral replication are clinically silent. Viral release into 
circulation increases slowly. Viral antigens appear in blood. HIV 
infection clinically manifests in 3 to 6 weeks post-exposure in up to 90% 
cases. 
 
 
  
ACUTE RETROVIRAL SYNDROME (ARVS) 
Increasing viraemia makes the infection manifest as „flu like‟ 
episode, called ARVS (sore throat, myalgia, fever, rash, fatigue, enlarged 
nodes, diarrhoea and vomiting). Proportionate to the viral load in blood, 
there is a downward spike in CD4 count. With virus dissemination to all 
lymph depots, the infection becomes  multi-systemic and permanent. Due 
to the host‟s immune response, viral replication is restrained. Symptoms 
abate in 2 to 4 weeks. CD4 count gets corrected. Patient is sero-
converted. He may be diagnosable, also by virus its components in blood. 
After recovery, the patient goes through a variable period of clinical 
latency. Two types of  „latent‟ phases are possible. 
 
VIRUS NON-PRODUCTIVE LATENT (VNPL) PHASE 
Persons with a strong immune response take care of total viral 
replication while the virus lurks in reservoirs, in peaceful coexistence, 
awaiting an opportunity to reactivate. This can continue for months to 
years. The patient is sero-positive, has no viral load in blood and has a 
normal immune profile. Cases in VNPL phase are clinically healthy and 
symptom-free. They may even be non-infective  to sex partners but are 
not safe blood donors. 
 
  
 
VIRUS LOW-PRODUCTIVE SUBDUED (VLPS) PHASE 
If the initial immune response is not strong enough to restrain viral 
replication completely, virus is produced in minute amount, but not 
sufficient to produce continuous clinical manifestations. The virus keeps 
on infecting new CD4 T-cells. Its replication steadily increases without 
causing a drop in their count. A period of apparent inaction continues 
over a variable period, depending upon the magnitude of viral replication. 
Patient is sero-positive. His viral load depends on the „set point‟. CD4 
count, usually normal, shows a trend of gradual annual decline (25 to60 
cells per year).Cases in VLPS phase are not totally symptom-free. They 
may have mild/moderate episodes of symptoms due to GIT lesions. In 
between the episodes, they do not appear seriously ill. There may be 
„non-alarming‟ weight loss. Their infectivity is proportional to viral load. 
 
PERSISTENT GENERALISED LYMPH ADENOPATHY (PGLA) 
Some cases in VLPS phase have PGLA. Enlarged nodes show 
nonspecific polyclonal hyperplasia of „B‟ and „T‟ cell areas. Abnormal 
antibodies and their effects may appear. Some cases may have few, mild 
symptoms (fever, rash, fatigue). Constitutional symptoms indicate that 
the next stage is imminent very soon. 
  
  
STAGE OF IMMUNODEFICIENCY (SIMD) 
Viral replication continues over a long period, playing havoc with 
the immune apparatus. CD4 T-cells play the role of an „orchestra 
conductor‟ for humoral immunity as well as CMI. Dysfunction of 
humoral immunity is indirect due to influences on B-cells. Dysfunction 
of CMI is the direct result of loss of T lymphocytes. Progressive, 
relentless loss and dysfunction of almost all subsets of immune competent 
T-cells are the major events. Lymph nodes, thymus, bone marrow, 
lymphoid depots in tissues and gastrointestinal tract get depleted of T-
cells. They show structural disorganisation and atrophy. CD4 and CD8 
cell counts in blood drop. SIMD invites opportunistic pathogens and 
activates the pre-existing latent ones. CD4 count in peripheral blood 
is used as an indicator of immune function. 
 
 It is however not a perfect guide. 2% of the total pool of CD4 cells 
is in blood; rest are in tissues. Even a minute change in the distribution 
can bring about a vast change in the count.  In some studies, CD4 
percentage was a better marker than CD4 count. As of today, CD4 count 
is used and has served as a useful   practical guide. The Time required for 
progress from infection to SIMD is variable. It depends on the summation 
of dynamics of viral replication and the host‟s anti-HIV immune 
response. It can be prolonged by ART regime. Usually, the period cannot 
  
be predicted with certainty, except in cases in VLPS, showing decline of 
CD4 count at a steady rate. SIMD is reached in 2 to 5 years in „rapid 
progressors‟. „Slow progressors‟ take more than 10 years. 8 to10 years is 
the period required for majority of the cases. Hallmarks of SIMD are 
increasing viral load, increasing titer of viral components in blood and 
CD4 count below 300/mL. Anill-understood group consists of patients in 
whom CD4 counts are below 300/mL and yet who show no 
manifestations of  immunodeficiency. Co-existing STD/TB/viral 
infections accelerate the onset of SIMD. SIMD aggravates these 
diseases. A vicious cycle is thus established. 
 
POSSIBLE CO-MORBIDITIES ASSOCIATED WITH HIV 
These are immune complex lesions, autoimmune lesions and 
hypergammaglobulinaemia. 
 
CLINICAL STAGING: 
This staging system has been developed since many countries and 
communities are not having facilities for CD 4 count 
Stage I: 
1. Persistent generalized lymphadenopathy 
2.Asymptomatic  
  
Stage II: 
1.Herpes zoster 
2. Angular chelitis 
3.Recurrent oral ulceration 
4. Papular pruritic eruptions 
5.weight loss under 10% of body weight 
6.Recurrent respiratory tract infections 
7.Fungal nail infections  
8.Seborrhoeic dermatitis 
 
Stage III: 
1.PTB 
2 Severe pneumonia, empyema, pyomyositis, bone infection, 
meningitis, bacteraemia 
3.Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
4.Weight loss over 10% of presumed or measured body weight 
5.Chronic diarrhoea for longer than one month 
6.Fever- intermittent or constant for longer than one month 
7.Oral candidiasis 
  
8.Oral hairy leukoplakia 
9.Severe unexplained anaemia (below 8 g/dl), neutropenia (below 
0.5 billion/l)chronic thrombocytopenia (below 50 billion/l) 
 
 Stage IV: 
1.Extrapulmonary cryptococcosis including meningitis 
2.Disseminated non-tuberculous mycobacteria infection 
3.Progressive multifocal leukoencephalopathy 
4.Chronic cryptosporidiosis 
5.Extrapulmonary tuberculosis 
6.Kaposi sarcoma 
7.Cytomegalovirus infection (retinitis or infection of other organs) 
8.HIV wasting syndrome 
9.Pneumocystis pneumonia 
10.Recurrent severe bacterial pneumonia 
11.Central nervous system toxoplasmosis 
12.HIV encephalopathy 
13.Chronic herpes simplex infection   
  
14.Oesophageal candidiasis (or candidiasis of trachea, bronchi or 
lungs 
15.Lymphoma (cerebral or B cell non-Hodgkin) 
16.Invasive cervical carcinoma 
17.Atypical disseminated leishmaniasis 
18.HIVnephropathy   
19.Chronicisosporiasis 
20.Extrapulmonaryhistoplasmosis, coccidiomycosis 
21.Recurrent septicaemia  
 
DIAGNOSIS OF HIV 
The World Health Organization (WHO) recommends the use of 
immunological assays for the diagnosis of HIV [35,36]. Immunological 
assays include ELISA and WESTERNBLOT ASSAY. ELISA used as 
screening  test it should not be used as confirmatory test. WESTERN 
BLOT is confirmative diagnostic test . In children less than 18 months of 
age virological assays can be used for screening to determine HIV 
infection against the background of antibodies transmitted from the 
mother [37]. 
 
  
TREATMENT OF HIV 
The most advances in Human immunodeficiency treatment have 
come from inhibiting enzyme activity .used by the HIV in its life cycle. 
ART drugs are broadly classified by the site of drug action. 
 
 Entry or fusion inhibitors interfere with fusion and replication of 
HIV into the infected cell. The CCR5 receptor antagonists bind to 
theCCR5 receptor on the surface of the CD4T-cell thereby blocking viral 
attachment to the Cell do not target the virus directly . 
 
Nucleoside reverse transcriptase inhibitors (NRTI) inhibit reverse 
transcriptase by incorporating into viral DNA strand .NRTI are 
competitive inhibitors. The non- nucleoside reverse transcriptase 
inhibitors (NNRTI) are non-competitive inhibitors of reverse 
transcriptase  enzyme. The protease inhibitors (PI) act by inhibiting the 
protease enzyme which is essential for assembly of new virions.  
  
  
 
 
 
 
 
FIG 6: Diagram showing HIV Life Cycle & Sites of  
Action Antiretroviral drug 
  
  
 
Integrase enzyme useful in integration  of viral DNA  into DNA of 
infected host cell. So RALTEGAVIR which is  integrase inhibitors will 
be useful in the treatment of HIV . The maturation 
inhibitors(BEVIRIMAT) bind with gag protein result in  blocking the 
conversion of the polyprotein into the mature capsid protein (p24).In 
1987, Zidovudine is the  first drug approved for Food and Drug 
Administration(FDA) which inhibits the reverse transcriptase . This was 
used as a monotherapy for several years with very limited efficacy and 
later it was successfully paired with lamivudine (3TC) and used as 
combination therapy. The discovery of other classes of antiretroviral 
drugs and potential development of resistance and cross-resistance to 
monotherapy warranted a switch from monotherapy to combination 
therapy. The introduction of viral load determination was crucial to prove 
this concept. This switch to combination antiretroviral therapy – highly 
active antiretroviral therapy (HAART)combination therapy prevents 
mutated forms  of  Human immunodeficiency virus  from evolving. 
 
Currently there are six classes of antiretrovirals with over 26 
different drugs used for treatment of HIV. These drugs are aimed at 
stopping HIV in its tracks by stopping the various stages of viral 
  
replication. These classes include nucleoside reverse transcriptase 
inhibitors (NRTI‟s) – Zidovudine 
1. Non-nucleoside reverse transcriptase inhibitors(NNRTI‟s)- 
Efavirenz 
2. Protease inhibitors (PI‟s)-Loprinavir 
3. Fusion inhibitors-Enfuviritide 
4. CCR5 antagonists –Aplaviroc 
5. Integrase inhibitors-Raltegavir [33-35] 
 
By the end of 2010, WHO reported that in middle and low income 
countries ART issued for 6,650,000 people  accounting for 47% coverage  
[38].Guidelines have been set forth by the WHO and each individual 
country on how to use and manage patients on HAART [39]. WHO 
recommended first-line therapy consist of an non nucleoside reverse 
transcriptase  inhibitor  plus  two Nucleoside reverse transcriptase  
inhibitor, one of which should be Zidovudine or Tenofovir .  Stavudine 
less commonly used in first-line regimens because of its well-recognized 
toxicities. Second-line ART consists of a ritonavir-boosted  protease 
inhibitor (PI) plus two NRTIs, atazanavir or lopinavirare  the preferred 
PIs [39]. 
  
  
NACO GUIDELINES ON INITIATION OF ART 
WHO 
Stage 
WHEN CD4 COUNT 
NOT AVAILABLE 
CD4 count (cells/mm
3 
) 
I. Do not treat Treat if CD4T cell count< 250 
(If between251-300, 
repeat it after 4 weeks) 
II. Do not treat 
III. Treat Treat if CD4T cell  count < 350 
IV. Treat 
Treat irrespective of CD4T 
cell count 
 
 
1. HIV/AIDS &TB  (Regimen should contain efavirenz): 
Pulmonary Tuberculosis & HIV/AIDS- start Anti retroviral therapy 
after 2 wks of initiation of Anti tuberculosis treatment  for all patients 
with CD4 < 350 cells/mm3.(for patients with CD4more than 350, defer 
ART.).Extra Pulmonary TB & HIV- start Anti retroviral therapy after 2 
wks of initiation of Anti Tuberculosis treatment  in all patients 
irrespective of CD4 count Currently the guide line mentions that if CD4 
>350, the patient needs to be re assessed for CD4 and clinical stage at 
completion of ATT. 
  
  
PREVENTIVE MEASURES FOR HIV 
The rate of new HIV infections and AIDS-related deaths has fallen 
globally resulting in a decline of the epidemic. Declines in new Human 
immunodeficiency virus  infections across the world have been reduced 
by access to antiretroviral therapy and the changes in behaviour via 
several intervention programs. ART coverage dramatically increased in 
sub-saharan Africa 20%  alone from 2009 to 2010. The best success seen 
is in programs to prevent the MTCT which can decrease  rates of 
transmission by 92-99%[40,41]. Preventing measures of MTCT 
 
1. USE of a combination of antiretrovirals during pregnancy  
2. After birth in the infant  potentially include bottle-feeding rather 
than Breastfeeding. 
 
No vaccine identified till now. However further research is on-
going in search of a truly effective vaccine [42,43]. Social strategies have 
proved effective in changing people‟s behaviour including sex education, 
provision of condoms both male and female, needle exchange programs, 
HIV testing centres, treatment of sexually transmitted infections  and the 
use of social media to educate people. These strategies have widely 
differing levels of efficacy and social acceptance. 
  
Other interventions include advocating male circumcision and the 
potential use of an antiretroviral based vaginal gel. Circumcision in men 
has been shown to reduce the risk of HIV infection in heterosexual men 
by between 38-66%.World health organisation and United nation AIDS 
recommend to prevent female to male HIV Transmission by circumcision 
[44]. Provision of HAART as pre-exposure prophylaxis has been shown 
to protect 96% of partners of HIV infected individuals . Post exposure 
prophylaxis with HAART is also recommended following needle-stick 
injuries or exposure to body fluids within the health care environment and 
to sexual assault victims. A Tenofovir containing vaginal gel, when used 
immediately before sex, reduces infection rates by approximately 40%  
[45]. 
 
TUBERCULOSIS 
HISTORY AND EPIDEMIOLOGY OF TUBERCULOSIS 
“With 2 billion persons, a third of the world population are 
estimated to be infected with mycobacteria” [46].The presence of 
tuberculosis (TB) can be traced back to centuries ago. Recently near  
eastern Mediterranean Scientists discovered the evidence of TB infection 
which is present since 9000 years ago[47]. Over time,  tuberculosis was 
known by many names including 
  
 
1. Contagion, 
2. Phthisis and  
3. White Plague.  
 
Scientists at the time believed death by tuberculosis was inevitable 
and that it was a contagious disease characterized by fever,  cough with 
expectoration , and decreased appetite and loss of weight [48]. It was not 
until 1882 when a physician Robert Koch  identified the casual agent of 
disease Mycobacterium tuberculosis, or Koch's bacillus by using a new 
staining method [49,50]. So March 24 known as World Tuberculosis Day 
[51]. 
 
Streptomycin is  the first effective anti-tuberculosis agent, was 
isolated  from organism and used for treatment of TB [52]. Although this 
monotherapy cured several people, a substantial number of people 
developed TB again (relapse) and later resistance to streptomycin was 
seen [53]. Streptomycin in combination with isonicotinic acid hydrazide 
(isoniazid) showed much better  outcomes and after rifampicin was 
discovered in 1957 the TB treatment was  revolutionized [54-56]. 
Ultimately, results of clinical trials led by the BMRC showed that a 4 
  
drug regimen including rifampicin and isoniazid  the most effective and 
reasonably  well-tolerated oral agents for active tuberculosis [57]. 
 
One in three people in the world is infected with Mycobacterium 
tuberculosis, however a relatively small proportion of infected people 
will go on to develop TB disease[58]. 
 
Tuberculosis remains a public health problem .Despite the 
availability of highly efficacious treatment for decades, . In 1993, World 
Health Organisation declared Tuberculosis a global public health 
emergency, at a time when an estimated seven to eight  million cases and 
one and half  million deaths occurred each year. There are 22 countries in 
the world which constitute 82% of global tuberculosis cases, and these 
are termed as 22 High-TB Burden countries. There were an estimated 
88lakhs  incident cases of Tuberculosis globally in 2010 
[59].Tuberculosis is the second leading cause of death from an infectious 
disease worldwide (after HIV), which caused an estimated 1.5 million 
deaths in 2010. Globally, decreasing in absolute number of occurrence of 
tuberculosis at an approximate rate of 1.3%per year since 2002. Likewise 
TB mortality has also been falling globally [60]. In 2010, 6.2 million 
people notified  to NTCP  as tuberculosis infected people. Of these, new 
one is 5.4 million, recurrent episode is 0.3 million. Globally, the ratio of 
Male to female ratio TB cases notified is 1.7. 
  
TRANSMISSION OF TB, THE SYMPTOMS AND SIGNS 
Mycobacterium tuberculosis (rod-shaped, non–spore-forming, 
aerobic bacterium) is spread by small airborne droplets, called droplet 
nuclei, generated by the coughing, sneezing, talking, or singing of a 
person with pulmonary or laryngeal tuberculosis. Factors influencing 
transmission: 
 
1. Number of bacilli in the droplets 
2. Virulence of the bacilli, exposure of the bacilli to contact  
3. Ultraviolet light 
4. Degree of ventilation. 
 
Introduction of Mycobacterium  tuberculosis leads to pneumonia, it 
can spread to pleura , lymphatics, central nervous system, bone, joints. 
For persons with immune competent individuals( intact CMI) the next 
defensive step is granuloma formation around the Mycobacterium 
tuberculosis organisms restricting growth and establishing latency, leads 
to healed lesions by the process of fibrosis and calcification. Primary 
progressive  tuberculosis is developed in Immune compromised  patients 
[86, 87].Even though many people infected with tuberculosis bacilli only 
10% will develop disease[88]. 
  
  
General  signs and symptoms  
1. Fever, chills, night sweats 
2. Loss of appetite, 
3. Weight loss 
4. Fatigue 
5. Finger clubbing may also occur . 
 
In patients with pulmonary TB along with the general symptoms 
they may also present with chest pain and coughing out blood.   EPTB 
occurs more commonly in immunosuppressed persons, commonly HIV 
patients and in young children. Common sites for extrapulmonary 
infection include the pleura, central nervous system( CNS) , lymphatic 
system, genitourinary system (GIT), and the bones and joints among 
others.  More severe  form of TB is called  “Disseminated or Miliary TB” 
makes up about 10% of extrapulmonary cases. Other signs of  EPTB 
depend on the affected organs. 
 
DIAGNOSIS OF TB 
Active TB may be considered as a possible diagnosis when patients 
present with  physical signs and symptoms suggestive of TB plus 
abnormal findings on a chest radiograph. The  chest x-ray  may show 
upper and middle lobe infiltrates and cavitations; however atypical 
  
features may be seen in    immuno-compromised patients. Traditionally, 
in spite of modern advances,  microscopic examination of a sputum smear 
or other diagnostic  specimen for the Existence of  AFB using the Ziehl-
Neelson staining is used to identify active TB. Identification of 
mycobacterium tuberculosis in culture medium is the confirmatory test. 
Löwenstein-Jensen , or Kirchner and the various Middlebrook 
formulations &New  MB/BacT (Biomerieux),BACTEC 9000  
(BectonDickinson), and the Mycobacterial Growth Indicator Tube are 
used for culture the organism. [61].  
 
Newer rapid automated DNA tests are being used for the diagnosis 
of  TB along with drug susceptibility testing . Presumptive diagnosis of 
pulmonary TB can be made in patients with abnormal  findings on a chest 
radiograph suggestive of TB, presenting with signs and symptoms of TB 
in spite of at least two acid fast bacilli smear negative.  
 
Diagnostic criteria  for Pulmonary TB should include:  
1. Radiographic  abnormalities consistent with active pulmonary TB 
2. No response to a course of broad-spectrum antibiotics 
3. A decision by a clinician to treat with a full course of anti-TB 
chemotherapy.  
  
4. A patient with positive culture but negative AFB sputum 
examinations is also a smear-negative case of pulmonary TB 
 
Extra pulmonary tuberculosis  diagnosis based on  
1.  one culture-positive specimen  
2,  Histological or strong clinical evidence consistent with  active  
Extrapulmonary disease 
3.  decision by a clinician to treat with a full course of anti-
tuberculosis treatment.  
Immunological diagnostic tests such as the Mantoux tuberculin skin 
test are of limited application due to cross reactivity and poor sensitivity. 
 
TREATMENT OF TB 
Directly Observed Treatment, Short-course (DOTS) was adopted 
by WHO and implemented in several countries and has been the gold 
standard of treatment [62]. According to DOTS Observer should observe 
at least initial 2 months of ATT &watching patients swallow their TB 
therapy. If DOTS has been implemented properly success rate may 
exceeding 95%. 
 
  
WHO has set up guidelines whose primary aim is to help NTCP  in 
setting Anti tuberculous treatment strategies. The first line drugs in the 
treatment of TB  are rifampicin, isoniazid, ethambutol and pyrazinamide. 
The second line consists of 6 classes of drugs including aminoglycosides, 
polypeptides, fluoroquinolones and thioamides. TB treatment is divided 
into a 2 months intensive phase that comprises all the 4 first line anti-TB 
drugs followed by 4 months continuation phase with rifampicin and 
isoniazid (2HRZE/4HR). WHO now recommends less chances of relapse 
and failure with 24 weeks course of Rifampicin However, despite all 
measures, the tuberculosis that is resistant against atleast to firstline anti-
tuberculosis treatment that is defined as multiple drug resistant 
tuberculosis (MDRTB)(is resistant at least to isoniazid and Rifampicin, 
the two most powerful first-line anti-TB drugs has been on the increase) . 
MDR-TB can develop  in sensitive Tuberculosis and this is always due to 
Poor compliance of  ATT . 20 months of ATT including second line 
drugs are recommended for MDR-TB . In 2006, WHO announced a new 
epidemic of Extensively Drug Resistant Tuberculosis XDR-TB is defined 
as resistance against RIFAMPICIN , ISONIAZID ,any member of the 
QUINOLONE family and at least one of the following second-line anti-
tuberculosis injectable drugs: KANAMYCIN, CAPREOMYCIN, OR 
AMIKACIN . 
  
HIV prevalence is closely associated with this type of tuberculosis. 
Currently the only available and most widely used vaccine is the  BCG 
which, while it is effective against disseminated Tuberculosis in 
childhood [63]. 
 
HIV AND TB CO-INFECTION  
EPIDEMIOLOGY OF HIV AND TB CO-INFECTION 
The HIV epidemic worsens the already  presentTuberculosis 
problem in poor countries it also  reviving old Tuberculosis in well 
resourced countries .Both TB and HIV are fatally synergistic. TB is the 
leading infectious killer of PLWHA and the most common opportunistic 
infection (OI) [64,65]. Almost one in four deaths that occurs among 
PLWHA is due to Tuberculosis. Human immunodeficiency virus 
promotes both the  progression of latent Tuberculosis  infection to  active 
disease and a relapse of the disease in previously treated patients: HIV 
positive patients  developed disease from tuberculosis infection 20-30 
times than HIV negative [66-69]. HIV affects the immune system and 
increases the probability of people acquiring new Tuberculosis  
infections. Tuberculosis may accelerate the progression of Human 
immune deficiency virus  from asymptomatic to symptomatic disease and 
  
even AIDS,  increases both mortality and the incidence of other 
opportunistic infections among PLWHA. 
Globally the number of TB patients who had been diagnosed with 
Human immunodeficiency  virus status reached2.1 million in 2010, 
equivalent to 34% of notified cases of Tuberculosis. Of the 8.8 million 
incident cases globally an estimated 1.1 million (13%) were found to be 
co-infected with HIV People with smear negative PTB &EPTB have high 
mortality rate since they are immune suppressed than smear positive PTB 
. Mortality rate reduced with anti retroviral therapy .Life expectancy and 
quality of life  improved with ART. 
 
THE IMPACT OF HIV CO-INFECTION AND ART IN TB 
PATIENTS 
In the presence of HIV-TB co-infection is associated with high 
mortality and morbidity, despite effective tuberculosis therapy. However, 
studies have revealed evidence which shows significant reduction in 
mortality among HIV co-infected tuberculosis patients who are 
appropriately initiated on antiretroviral therapy during the course of 
tuberculosis  treatment (Karim et al, 2010).  
 
The results of this study showed that the starting of ART   during 
tuberculosis therapy in patients with confirmed HIV/Tuberculosis co-
  
infection reduced mortality by 56% and that a delay in initiating 
Antiretroviral therapy increased the  death rate from 6.5 per 100 person-
years to 14.5 per 100 person-years when the initiation of  ART was 
delayed until the completion of ATT. It was also noted that the interval 
between the end of  the anti tuberculosis treatment and the starting of 
ART is  important, because a significant  number of deaths in the 
sequential therapy group occurred during this period.  
 
A study  conducted in a rural province in THAILAND expressed 
that decrease in the risk of  death during ATT for   patients receiving 
Antiretroviral therapy(Akksilp et. al., 2007). A similar population-based 
study was conducted across four provinces in Thailand between October 
2004 and March 2006 (Sanguanwongse, 2008). The results of the study 
indicated  that only11% of TB/HIV co-infected patients started on ART 
died compared to 46% of the co-infected patients for whom ART was not 
prescribed.  Even for those with very low CD4 counts (<10cells/ml) 21% 
of the patients receiving ART died, compared with 81% of those not 
receiving ART. Sanguanwongse (2008) concluded that the risk of death 
among HIV co-infected TB patients who were not receiving ART was six 
times greater than the risk of death among HIV co-infected TB patients 
receiving ART in the resource-limited public health setting in Thailand.  
  
  
The literature reviewed suggests that both single site-based and 
population-based studies provide evidence which shows that the 
appropriate initiation of Antiretroviral therapy during anti tuberculosis 
therapy  significantly reduces mortality among HIV Tuberculosis co-
infected patients. 
 
FACTORS INFLUENCING THE INITIATION OF ART DURING 
TB TREATMENT 
The combination of antiretroviral therapy with tuberculosis 
treatment results in a rapid reduction in the incidence of other 
opportunistic infections, because ART restores pathogen- specific 
immune responses (Lawn, 2009). Despite all the evidence supporting the 
concomitant treatment of both diseases in HIV/TB co-infected patients, 
ART is often  deferred in co-infected patients, sometimes until the 
completion of ATT, due to  potential drug interactions between 
rifampicin and some classes of ART drugs, IRIS, the overlapping side-
effects of TB drugs and antiretroviral drugs, the high pill burden, and 
programmatic challenges (Karim et. al., 2010)Concurrent administration 
of ART and TB medicines is complicated by the overlapping side-effects 
of both therapies and the fact that rifamycins (rifampicin, rifapentine, 
rifabutin) tend to decrease the serum levels of non-nucleoside reverse 
transcriptase inhibitors and protease inhibitors. Thus, the simultaneous 
  
administration of these medicines needs meticulous drug selection, dose 
modifications and close therapeutic drug monitoring (Lawn, 2009). 
 
The problem of patients refusing ART is not unique to one country. 
Maisels (2004) reported that 57% of eligible patients who did not receive 
ART declined this intervention when it was recommended by the 
provider following a review of medical records at a Community Health 
Centre in the USA, with the aim of determining the reasons why certain 
eligible patients did not receive ART between 1997 and 1998. 
 
Reasons for declining 
1. ART were not being ready for strict adherence to a complex 
regimen (7 of 16) 
2. Fear of  the side effects (6 of 16).  
3. Active drug use, religious beliefs, homelessness, confidentiality 
concerns 
4. Depression and feeling well without HAART 
5. Homelessness, depression. 
  
  
The total distance travelled by patients to an ART site and the cost 
of the transport  involved have also been proven to have an influence on 
the acceptance of antiretroviral  therapy among TB patients co-infected 
with HIV.A study of HIV/TB co-infected patients whose participants 
were drawn from Zambia and South Africa also showed (Bond et. al., 
2009).  
 
The required expenditure on transport in relation to the distance 
travelled to reach the healthcare facility was not  affordable for some 
patients , resulting in either a late or a failure to initiate Antiretroviral 
therapy. However, antiretroviral therapy was more readily available  for 
households of low socio-economic status because of the shorter distances 
travelled to health facilities, the availability of  disability grants, and their 
less absolute poverty. Travelling long distances to health facilities also 
proved to be a limitation on the availability of ART in the rural parts of 
the Eastern Cape Province in South Africa (Bond et. al., 2009). 
 
TREATMENT OF HIV-TB CO-INFECTION 
Since the world health organisation declared  in 1993 that 
Tuberculosis was a global emergency, the Directly Observed Treatment 
Short course  strategy has been the key public health intervention that has 
been widely used to affect global Tuberculosis control [70]. Improved 
  
survival rate and Tuberculosis outcome in ART treating patients [71,72]. 
In addition, ART  decreases Tuberculosis  rates 
 
1. By 90% at an individual level 
2. By 60% at a population level  
3. It reduces TB recurrence rates by 50% . 
 
Immuno-pathological reactions, termed "the immune  
reconstitution Inflammatory syndrome" (IRIS), occur most commonly  
when ART is initiated in patients with tuberculosis (paradoxical 
Tuberculosis-associated IRIS), or in which HAART therapy results in 
new presentation of previously undetected (likely subclinical) TB 
infection (unmasking TB-associated IRIS). Reports estimating the  
prevalence of TB-IRIS in patients with undergoing new ARVs are 
variable, ranging from as low as 7.6% in one to as high as 32%. 
Clinically it manifests as fever and coarsening or appearance of 
pulmonary infiltrates, lymphnode enlargements, serous cavity 
effusions or intracranial tuberculomas, subcutaneous abscess in 
patients with miliary TB, rarely acute respiratory syndrome(ARDS) 
and acute renal failure can develop. It usually develops after 6 weeks 
of course of ART. However ATT and HAART need to be continued 
without interruption. 
  
First-line HAART regimen should  contain two NRTIs  plus one 
NNRTI . The ideal NRTI is zidovudine or tenofovir combined with either 
lamivudine or emtricitabine. For the NNRTI, efavirenz preferred over 
nevirapine due to fewer adverse  reactions. According to WHO Anti 
tuberculosis treatment should initiated before Antiretroviral therapy. 
Antituberculosis treatment should be started immediately who is already 
on ART  and HAART needs to be revised to prevent possible drug-drug 
interactions In all HIV tuberculosis co-infection patients, co-trimoxazole 
preventive therapy (CPT)  for  pneumocystis jiroverci should be started 
and continued throughout anti tuberculous treatment . CPT substantially 
decreases death rate  in HIV-positive TB patients .Treatment strategies 
HIV TUBERCULOSIS co infection: 
 
1. Pulmonary Tuberculosis with CD4 count <50cells/µl or extra 
Pulmonary TB – start ART immediately following ATT 
2. Pulmonary Tuberculosis with CD4 count 50-200cells/µl  - start 
ART after 2 months of ATT 
3. Pulmonary tuberculosis with CD4 count >200 cells/µl –treat 
tuberculosis  start ART after completion of anti tuberculosis 
treatment 
  
CHALLENGES OF DIAGNOSING AND TREATING 
TUBERCULOSIS AND HIV 
The first challenge of diagnosing TB lies in the fact that a sizeable 
proportion of patients in countries with high TB incidence do not seek 
medical attention for their symptoms early enough. A high proportion of 
those who choose to seek medical care do so late in the natural history of 
the disease.  TB in many cases has an insidious onset with initially few 
non specific symptoms so that patients may seek care late and the health 
care workers for the same reason may not think of TB when the patient 
presents. The primary method, sputum smear examination, currently used 
most for diagnosing TB in low resource-limited settings has limited 
sensitivity; the patient may visit the TB diagnostic facility several times 
before  achieving a diagnosis of TB. 
 
Assessing diagnostic delay in HIV disease is a bit more difficult 
due to the long latency Period and the subtle and insidious onset of the 
disease symptoms that can stretch for several Months or even several 
years. Most HIV infections are symptomless until quite substantial 
immunological damage has occurred. In terms of diagnostic delay, 40% 
or more of  HIV infected patients have advanced disease at the time of 
HIV diagnosis. A study carried out in two tertiary hospitals in Uganda, 
showed that although HIV test uptake was high at 98%  among admitted 
  
patients, 81% of these patients were being tested for HIV infection for the 
first time. Among patients who were tested for HIV during 
hospitalization in an urban tertiary hospital, 64% turned out to be HIV 
infected. Waiting to be tested for the first time for HIV infection until 
admission in a tertiary institution means a quite substantial delay. 
Additional challenges are present regarding the optimal timing for 
starting of combination ART in patients co-infected with Tuberculosis. 
 
The second challenge in the diagnosis and treatment of these two 
diseases is getting people to take diagnostic tests and get test results. The 
success of any TB (and possibly to some extent HIV) control programme 
lies in detecting the cases and starting eligible patients on good quality 
treatments. In primary health care programmes it is crucial that HIV 
patients are diagnosed early in their disease process to avoid challenges 
of deciding when to start treatments in the setting of co-infections and 
vice versa. Moreover cART reduces mortality among TB patients. 
Despite the adoption by many countries of the WHO provider initiated 
HIV testing and counseling guidelines, uptake of HIV testing is still low 
in outpatient departments, also among TB patients. A study in Ethiopia 
found missed   opportunities for HIV diagnosis in 52% of patients. 
  
  
The third challenge in the TB and HIV treatment programmes is to 
maintain those patients on treatment who have initiated therapy. High 
defaulting levels from anti-tuberculosis treatment (range 11-30%) have 
been reported in Africa. Similar to what is seen in TBtreatment, between 
16% to 26% on cART have been lost to follow-up within three years of 
starting cART in resource-limited settings.  
 
Data concerning defaulting or loss to follow up from ART 
programmes are still limited. The fourth challenge in treating TB and 
HIV diseases is the poor adherence to treatments among those patients 
who do not abandon their treatments. Despite the high adherence levels 
reported for patients who remain on their cART or TB treatments, a 
sizeable proportion of  patients adhere poorly to their treatments. 
Importantly, the on-and-off interruptions in medications result in drug 
resistance. Good adherence to TB treatment is essential for cure from the 
disease and  plays a crucial role in TB control.  
 
Similarly, good adherence to cART is critical for achieving viral 
suppression and good clinical outcomes. 
  
  
STUDIES IN PATIENTS WITH CO-INFECTION 
A study conducted in Portugal to assess factors of an poor 
Tuberculosis outcome (no cure or death) and to assess factors  of non-
adherence in HIV positive TB patients on ART, showed that 32.9% of 
patients were non-adherent to treatment and that 22.9% had an 
unfavorable outcome. Non-adherence was found to be the only predictor 
of an unfavorable outcome and adherence was independently associated 
with I.V. drug use, treatment complications and use of methadone. 
 
 In this study, the sample size was small (70 patients), and the 
timing of ART initiation was not mentioned [73].A retrospective cohort 
study done in England to assess the benefits ,risks of administering ART 
during the treatment of Tuberculosis in HIV infected patients showed that 
there was a significant decrease in viral load and AIDS defining illness in 
those who were initiated on ART, as well as a decrease in mortality. In 
addition, there was a Significant association between the occurrences of 
adverse events and use of ART.10% of patients had paradoxical 
worsening, 90% of whom were on ART. The authors point out the fact 
that the occurrence of AE could potentially influence adherence to either 
disease but there was no evidence of it in the study [74]. 
A study conducted in Malawi to assess whether Antiretroviral 
therapy reduces case fatality in HIV positive patients with TB, in which 
  
patients who received Antiretroviral therapy in the continuation phase of  
anti tuberculosis treatment were compared to those who didn‟t receive 
Antiretroviral therapy  showed that ART  started in the continuation 
phase didn‟t have any effect in reducing case fatality (6 out of ten deaths 
occur in the intensive phase).Similarly, the other treatment outcomes 
were also similar in the two groups e.g. treatment success, loss to follow 
up, although that was not  discussed by the authors. The limitation in this 
study is that the two groups compared were patients who accepted and 
those who refused ART, hence there might be differences in economic or 
social status between the groups which influenced treatment outcome 
[75] 
 
Another study was also conducted in Malawi to compare 6-month 
and 12-month cohort treatment outcomes of HIV positive Tuberculosis 
patients and HIV positive non Tuberculosis  patients treated with Anti 
retroviral therapy , and this study revealed that those people with TB had 
a significantly lesser default rate and the authors discussed that it was 
possibly due to the fact that these patients had time to stabilize and 
prepare for their ART since they were started on Antiretroviral therapy 
only in the continuation phase of  anti tuberculosis treatment, whereas the 
other patients were started on anti retroviral therapy  in a short time [76]. 
Thus, this can indicate that adherence to either treatment (anti-TB or 
  
ART) might be a challenge for those patients who initiate the anti 
retroviral therapy drugs in the  intensive phase of anti-tuberculosis  
treatment. A study conducted in Nigeria to compare the outcomes  of 
HIV –TB Positive and HIV -TB negative patients showed that default 
rate, which was 17% overall was not significantly related to Human 
immuno deficiency status, although more Human immunodeficiency 
positive than Human immunodeficiency  negative patients defaulted from 
treatment. It was also found that reasons for default to TB treatment in the 
HIV positive patients included: severely ill patients going back their 
home town to receive support from their extended families; patients 
leaving the area to consult healers that advertised that they would cure 
HIV; seriously ill patients not being able to come to collect their drugs 
personally; stigma and discrimination forcing some HIV positive patients 
to relocate, mainly those with HIV wasting and other obvious HIV related 
symptoms. The study showed a significant difference in mortality 
(15.5%in HIV positives VS 3.1% in HIV negatives.)The HIV positive 
patients were not on ART in this study [77]. 
Two studies conducted in England also showed that paradoxical 
reactions during TB treatment were more common in co-infected patients 
receiving ART, mainly when  introduced early [78]; adverse events also 
occurred more frequently in Human immunodeficiency virus  positive 
  
patients in one study comparing Human immune deficiency  negative 
patients with HIV positive patients (of whom 70% received ART).But 
despite a higher rate of serious side effects such as    persistent vomiting,  
rash, hepatotoxicity, peripheral neuropathy,  in the HIV positive 
individuals, TB treatment discontinuation was similar in the two groups 
[79]. 
 
Two studies on adherence to TB preventive therapy in HIV 
positive patients showed high rates of default. 26.5% of patients defaulted 
from preventive treatment in Thailand, with migration for job search, 
denial of HIV status, perceived drug side effects, and confusion about the 
duration of treatment being associated with defaulting. Married people, 
women, outpatients, surviving spouses, the self-employed, and those with 
no history of physical symptoms were more likely to be adherent to the 
treatment [80].Similarly in South Africa, more than half of HIV patients 
initiated on TB preventive treatment interrupted it. [81]. 
  
  
RCT  SHOWING  SURVIVAL  BENEFITS  OF  EARLY ANTI 
RETROVIRAL THERAPY  INITIATION 
Karim et al. (2010) conducted the trial in Durban , South Africa 
“Starting Antiretroviral  Therapy at Three Points in Tuberculosis 
(SAPIT)” . They identified the  patients with CD4 counts lower than five 
hundred cells per Litre, death rate was lower for patients assigned to start 
ART while on TB treatment than for those who were assigned to 
complete TB treatment before initiating ART.  
 
This result held true in subsets of patients with CD4 counts above 
and below 200 cells/_L. Although the incidence of TB-associated IRIS 
was higher amongst  patients assigned to initiate ART while on TB 
treatment, no deaths were attributable to TB-associated IRIS. No 
difference was found in the proportions of patients being diagnosed with 
grade 3 or 4 adverse events  (other than IRIS).Philpott and Schuklenk 
(2010); Wilson and Meintjes (2010) and Boulle et al.(2010a) critiqued the 
study by Karimet al. (2010), saying that People with HIV infected with 
CD4 T cell count less than 200 cells/ul should not have been randomized 
to receiving ART after ATT completed. They argued that it was 
predictable based on prior observational studies that patients with  CD4T 
cell counts less than 200 cells/Ul would  have increased  mortality if they 
only  started ART after TB treatment rather than during TB treatment.  
  
In addition, the 2004 South African ART guidelines (in force at the 
start of the SAPIT trial) recommended that patients having tuberculosis 
with CD4 count less than 200 cells/l should start anti retroviral therapy 
after completing 2 months of anti tuberculosis treatment (or after 
completing two weeks and as soon as they are tolerating anti tuberculosis 
treatment if the patients CD4 counts were below 50cells/_L). 
 
Cohen (2010), however, reports some clinicians and public health 
officials as saying that the criticism by Philpott and Schuklenk (2010) 
was too negative and that the results from this study would be helpful in 
assuring clinicians that starting Anti retroviral therapy  during treatment 
for tuberculosis treatment does significantly reduce mortality. The SAPIT 
study also included a comparison of patients starting Anti retroviral 
therapy  within the one month  of Tuberculosis treatment(early ART), 
versus within one month of the  continuation phase of Tuberculosis 
treatment (late ART). Karim et al. (2011) found an increased risk of IRIS 
(Incidence-Rate Ratio (IRR) 2.62, 95% CI: 1.48-4.82) and of switching 
antiretroviral drugs as a result of adverse events (10 versus 1, p = 0.006) 
for patients receiving early ART compared to late ART, but no overall 
AIDS-free survival benefit ,The median CD4 count was 150 cells/_L and 
did not differ between groups. 
  
 In a subset of patients with CD4 cell counts lower than50 cells/_L 
however, Karim et al. (2011) found a reduction in the combined 
incidence of AIDS or death (IRR 0.32, 95% CI: 0.07-1.13) that they 
suggest outweighs the risks of IRIS (IRR 4.71, 95% CI: 1.48-19.64) and 
the need to switch ART because of side effects  (3 versus 0 patients) for 
patients starting ART earlier versus later with respect to the time they 
started TB treatment. 
 
Another randomized controlled trial comparing mortality among 
Patients with differing times of starting ART after  starting 
antituberculosis treatment was performed by Blanc et al. (2011) among  
HIV positive Cambodian patients.  This study only included patients with 
CD4 counts lower than 200 cells/_L that had a Tuberculosis diagnosis 
confirmed by a AFB smear positivity Blanc et al. (2011) found that 
patients initiating ART two weeks after starting TB treatment  had a 
lower hazard of death than those starting ART eight weeks after the start 
of anti tuberculosis treatment. Since median CD4 count for all patients 
was very low (25 cells/_L) this result is consistent with that of Karim et 
al. (2011).A third study that investigated the optimal timing of initiating 
ART during TB treatment was conducted by Havlir et al. (2011). 
 
  
 They enrolled patients from four continents who had confirmed or 
probable TB diagnoses and CD4 counts lower than 250 (median 77) 
cells/_L. There are decreased proportion  of patients dying or 
experiencing a  previously undiagnosed Event that indicates AIDS  in the 
subset of patients with CD4 counts lower than fifty cells/L (15.5% versus 
26.6%, 95% CI: 1.5-20.5) for Early  group (within 2 weeks of initiating 
treatment for TB) versus later (8-12 weeks after initiating treatment for 
TB).  
 
For patients with CD4 cell counts of 50 cells/_L or greater, the 
difference in proportions of patients dying and experiencing AIDS-
defining events was not statistically significant (p  0.67) for those starting 
ART earlier versus later. Havlir et al. (2011) did find an increased 
proportion of patients being diagnosed with TB-associated IRIS in the 
earlier ART compared to the later ART group (11% versus 5%, p 
=0.002), but no deaths were attributed to TB-associated IRIS. 
 
There is no significant difference in  drug toxicity or Laboratory 
abnormalities in patients who started ART earlier versus later. Despite the 
greater risk of patients developing IRIS and needing to switch 
antiretroviral drugs as a result of toxicity, all three studies {Havlir et al, 
Karim et al,Blanc et al}  are in agreement that early ART initiation (two 
  
to four weeks after starting TB treatment) is associated with lower 
mortality for patients having very low CD4 counts (lower than 50 
cells/_L or a median of 25 cells/_L) 
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MATERIALS AND METHODS 
SOURCE OF DATA 
This study was conducted at Mahatma Gandhi Memorial 
Government Hospital ,Trichy in collaboration with ART CENTRE in our 
institution . 
 
STUDY DESIGN 
Unicentric prospective comparative study 
 
PERIOD OF STUDY 
January 2013  to September 2014 
 
ETHICS COMMITTEE APPROVAL 
Approval was obtained from Institutional ethics committee. 
 
INCLUSION CRITERIA 
 Age > 18 
 Documented history  of  HIV-TB co-infection in Out-patient or 
inpatient 
 Consent to the study  
  
  
EXCLUSION CRITERIA 
 Age <18 
 Diabetic, chronic renal disease, Known case of hypertension 
 Patients who are already on ART now diagnosed to have 
Tuberculosis 
 
CONSENT 
Informed consent was obtained from the patient in both groups 
 
METHOD 
HIV -TB co-infected individuals on ATT are entered into the 
groups early (2-8 weeks) and delayed(>8weeks) according to time of 
presentation.  All patients were thoroughly examined and basic 
investigations were taken categorised according to RNTCP guidelines 
and started on ATT. NACO provided the antiretroviral drugs free of cost. 
Patients followed for 12 months regarding side effects, IRIS,TB outcome, 
HIV  progression,CD4 count. 
  
  
 
 
 
RESULTS  
  
 
RESULTS 
 
FREQUENCY TABLE 
 
TABLE 1.AGE 
Particulars 
No. of respondents 
(n=60) 
Percentage 
(100%) 
Below 20yrs 
2 
 
3.3 
21-30Yrs 9 15 
31-40yrs 23 38.3 
Above 40yrs 26 43.3 
 
  
  
 
 
FIG  1.AGE 
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TABLE 2.SEX 
Particulars 
No. of respondents 
(n=60) 
Percentage 
(100%) 
Male 36 60.0 
Female 24 40.0 
 
FIG 2.SEX 
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TAB.3.INTERVEVAL BETWEEN ART AFTER ATT 
Particulars 
No. of respondents 
(n=60) 
Percentage 
(100%) 
2 to 8 weeks 30 50.0 
More than 8 weeks 30 50.0 
 
 
TAB.4. TUBERCULOSIS TREATMENT CATEGORY 
 
  
Particulars 
No. of respondents 
(n=60) 
Percentage 
(100%) 
CAT-1 58 96.7 
CAT-2 2 3.3 
  
 
TAB.5 . IRIS 
Particulars 
No. of respondents 
(n=60) 
Percentage 
(100%) 
Nil 56 91.6 
Fever 2 3.3 
INC NODE 1 1.7 
INC PLU 1 1.7 
INC PUL 1 1.7 
 
  
  
 
FIG.3.  IRIS 
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TABLE 6..HB 
Particulars 
No. of respondents 
(n=60) 
Percentage 
(100%) 
Less than 8 5 8.3 
More than 8 55 91.7 
 
 
   TABLE 7.SITE OF TB 
Particulars 
No. of respondents 
(n=60) 
Percentage 
(100%) 
EXTRA PULMONARY TB 6 10.0 
PULMONARY TB 54 90.0 
 
 
 
 
 
 
  
 
 
FIG 4.SITE OF TB 
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TABLE 8. SPUTUM 
Particulars 
No. of respondents 
(n=60) 
Percentage 
(100%) 
NO SPUTUM 6 10.0 
AFB NEGATIVE 49 81.7 
AFB POSITIVE 5 8.3 
 
 
 
TABLE 9.ADVERSE EFFECTS 
Particulars 
No. of respondents 
(n=60) 
Percentage 
(100%) 
Nil 57 95.0 
Anemia 1 1.7 
Hepatitis 2 3.3 
 
  
  
TABLE 10.OUTCOME 
Particulars 
No. of respondents 
(n=60) 
Percentage 
(100%) 
Complete 58 96.7 
Died AFT 2 3.3 
 
Table 11, Mean CD4 count in early and delayed ART groups 
Q17A.B CD-4 MEAN CD 4 COUNT 
2 to 8 weeks (n=30) 170.33 
More than 8 weeks (n=30) 152.17 
Q17B.6 CD-4 
 
2 to 8 weeks (n=30) 211.93 
More than 8 weeks (n=30) 158.37 
Q17C.12 CD-4 
 
2 to 8 weeks (n=30) 264.93 
More than 8 weeks (n=30) 174.6 
 
 
  
 
FIG 5, Mean CD4 count in early and delayed ART groups 
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DESCRIPTIVE STATISTICS 
Item  Min Max Mean S.D 
Q2.AGE 18 58 39.05 9.615 
Q7.DUR 2 16 6.67 3.620 
Q10.HB 6.10 13.00 9.8983 1.29830 
Q11.TC 3658 10456 6778.27 1880.770 
Q12A.ESR 13 100 43.72 20.804 
Q12B.ESR 21 150 57.85 25.311 
Q13.B.UREA 20 55 37.85 6.351 
Q14.S.CREAT .40 1.80 .8647 .31973 
Q15.A LIVER ENZYMES 
(AST) 
25 59 40.93 7.974 
Q15.B LIVER ENZYMES 
(ALT) 
25 62 39.98 7.626 
Q15.C.2 LIVER ENZYMES 
(AST) 
30 112 43.77 14.269 
Q15.D LIVER ENZYMES 
(ALT) 
29 234 45.32 29.034 
  
 
  
Q15.E.4 LIVER ENZYMES 
(AST) 
30 130 43.78 18.700 
Q15.f.4 LIVER ENZYMES 
(ALT) 
29 150 42.60 18.161 
Q17A.B CD-4 53 310 161.25 71.190 
Q17B.6 CD-4 52 486 185.15 87.320 
Q17C.12 CD-4 80 646 219.77 112.633 
  
T-Test 
 Mean S.D 
Statistical 
Inference 
Q2.AGE    
2 to 8 weeks (n=30) 39.33 7.689 T=.226 df=58 
.822>0.05 
Not Significant 
More than 8 weeks (n=30) 38.77 11.349 
Q7.DURATION    
2 to 8 weeks (n=30) 3.40 1.221 T=-16.706 df=58 
.000<0.05 
Significant 
More than 8 weeks (n=30) 9.93 1.760 
Q10.HB    
2 to 8 weeks (n=30) 10.0233 1.44023 T=.743 df=58 
.461>0.05 
Not Significant 
More than 8 weeks (n=30) 9.7733 1.15009 
Q11.TC    
2 to 8 weeks (n=30) 6747.93 1800.788 T=-.124 df=58 
.902>0.05 
Not Significant 
More than 8 weeks (n=30) 6808.60 1987.921 
Q12A.ESR    
2 to 8 weeks (n=30) 43.57 22.295 T=-.055 df=58 
.956>0.05 
Not Significant 
More than 8 weeks (n=30) 43.87 19.581 
  
    
Q12B.ESR    
2 to 8 weeks (n=30) 56.70 25.115 T=-.349 df=58 
.728>0.05 
Not Significant 
More than 8 weeks (n=30) 59.00 25.882 
 
 
Q13.B.UREA 
   
2 to 8 weeks (n=30) 36.53 5.740 T=-1.628 df=58 
.109>0.05 
Not Significant 
More than 8 weeks (n=30) 39.17 6.747 
Q14.S.CREATININE    
2 to 8 weeks (n=30) .8193 .28292 T=-1.100 df=58 
.276>0.05 
Not Significant 
More than 8 weeks (n=30) .9100 .35170 
Q15.A LIVER ENZYMES 
(AST) 
   
2 to 8 weeks (n=30) 39.03 8.704 T=-1.885 df=58 
.064>0.05 
Not Significant 
More than 8 weeks (n=30) 42.83 6.793 
Q15.B LIVER ENZYMES 
(ALT) 
   
2 to 8 weeks (n=30) 38.70 8.643 T=-1.311 df=58 
  
More than 8 weeks (n=30) 41.27 6.341 
.195>0.05 
Not Significant 
Q15.C.2 LIVER ENZYMES 
(AST) 
   
2 to 8 weeks (n=30) 45.07 19.104 T=.703 df=58 
.485>0.05 
Not Significant 
More than 8 weeks (n=30) 42.47 6.766 
Q15.D LIVER ENZYMES 
(ALT) 
   
2 to 8 weeks (n=30) 48.90 40.381 T=.955 df=58 
.343>0.05 
Not Significant 
More than 8 weeks (n=30) 41.73 7.602 
Q15.E.4 LIVER ENZYMES 
(AST) 
   
2 to 8 weeks (n=30) 46.43 25.561 T=1.100 df=58 
.276>0.05 
Not Significant 
 
More than 8 weeks (n=30) 41.13 6.601 
Q15.f.4 LIVER ENZYMES 
(ALT) 
   
2 to 8 weeks (n=30) 44.37 25.091 T=.751 df=58 
.456>0.05 
Not Significant 
More than 8 weeks (n=30) 40.83 5.919 
Q17A.B CD-4    
  
2 to 8 weeks (n=30) 170.33 77.064 T=.988 df=58 
.327>0.05 
Not Significant 
More than 8 weeks (n=30) 152.17 64.815 
Q17B.6 CD-4    
2 to 8 weeks (n=30) 211.93 101.137 T=2.477 df=58 
.016<0.05 
Significant 
More than 8 weeks (n=30) 158.37 61.640 
Q17C.12 CD-4    
2 to 8 weeks (n=30) 264.93 133.098 T=3.367 df=58 
.001<0.05 
Significant 
More than 8 weeks (n=30) 174.60 62.243 
 
  
Tables 
 
 
Q7.DUR 
Statistical 
inference 
2 to 8 
weeks 
(n=30) 
More than 
8 weeks 
(n=30) 
Total 
(n=60) 
Q2.AGE     
Below 40yrs 19(63.3%) 15(50%) 34(56.7%) X
2
=1.086 df=1 
.297>0.05 
Not Significant 
Above 40yrs 11(36.7%) 15(50%) 26(43.3%) 
Q3.SEX     
Male 20(66.7%) 16(53.3%) 36(60%) X
2
=1.111 df=1 
.292>0.05 
Not Significant 
Female 10(33.3%) 14(46.7%) 24(40%) 
Q8.TB RX     
CAT-1 28(93.3%) 30(100%) 58(96.7%) X
2
=2.069 df=1 
.150>0.05 
Not Significant 
CAT-2 2(6.7%) 0 2(3.3%) 
Q9.IRIS     
Nil 26(87%) 29(96.7%) 55(91.7%) X
2
=2.071 df=3 
.344<0.05 
Not  
Significant 
Fever 1(3.3%) 1(3.3%) 2(3.3%) 
INC NODE 1(3.3%) 0 1(1.7%) 
INC PLU 1(3.3%) 0 1(1.7%) 
  
INC PUL 1(3.3%) 0 1(1.7%) 
Q10.HB     
Less than 8 3(10%) 2(6.7%) 5(8.3%) X
2
=.218 df=1 
.640>0.05 
Not Significant 
More than 8 27(90%) 28(93.3%) 55(91.7%) 
q18.SITE     
EXTRA 
PULMONARY 
TB 
4(13.3%) 2(6.7%) 6(10%) 
X
2
=.741 df=1 
.389>0.05 
Not Significant PULMONARY 
TB 
26(86.7%) 28(93.3%) 54(90%) 
q19a.B 
SPUTUM 
    
NO SPUTUM 4(13.3%) 2(6.7%) 6(10%) X
2
=2.977 df=2 
.226>0.05 
Not Significant 
AFB 
NEGATIVE 
22(73.3%) 27(90%) 49(81.7%) 
AFB POSITIVE 4(13.3%) 1(3.3%) 5(8.3%) 
Q19b.2 
SPUTUM 
    
NO SPUTUM 26(86.7%) 28(93.3%) 54(90%) X
2
=.741 df=1 
.389>0.05 
Not Significant 
AFB 
NEGATIVE 
4(13.3%) 2(6.7%) 6(10%) 
  
q19c.6 
SPUTUM 
    
NO SPUTUM 26(86.7%) 28(93.3%) 54(90%) X
2
=.741 df=1 
.389>0.05 
Not Significant 
AFB 
NEGATIVE 
4(13.3%) 2(6.7%) 6(10%) 
q20.A/E     
Nil 28(93.3%) 29(96.7%) 57(95%) X
2
=3.018 df=2 
.221>0.05 
Not Significant 
Anaemia 0 1(3.3%) 1(1.7%) 
Hepatitis 2(6.7%) 0 2(3.3%) 
q21.outcome     
Completed 29(96.7%) 29(96.7%) 58(96.7%) X
2
=.000 df=1 
1.000>0.05 
Not Significant 
Died after  ATT 1(3.3%) 1(3.3%) 2(3.3%) 
    
 
  
  
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
  
  
DISCUSSION 
 
This study was conducted to determine optimal time to initiate 
ART in HIV – TB co-infected patients on ATT. The study population 
was 60 adults presenting to MGMGH from the period JAN 2013 to SEP 
2014. 
 
AGE WISE DISTRIBUTION (TABLE 1) 
of the total number of patients who presented with HIV TB Co –
infection43.3% were in above 40 yrs of  age group35.3% were in31-40yrs 
of age group15% belong to21-30yrs of age group Remaining 3.3% in less 
than 20 yrs of age group .20% 0f above 40 yrs of group were in early 
antiretroviral therapy group, remaining 23.3% were  in late antiretroviral 
therapy. 25%of 31-40 yrs age group were in early ART group,  
remaining10.3%   were in late ART group. 6.6% of 21-30 yrs age group 
were in early ART and 8.3% were in  late ART group 
 
SEX WISE DISTRIBUTION (TABLE 2) 
60%   (36 out of 60) of patients in this study were males, of these 
33%( 20 out of 60)   were in early group, 27% (16 out of 60)were in late 
group. 
  
40% ( 24 out of 60) of patients in this study were females, of these 
17% (10 out of 60) were in early group, 23% ( 14 out of 60) were in late 
group. 
 
ATT CATEGORY AND SITE OF TUBERCULOSIS (TABLE3&7 ) 
In this study 58 patients were started on category 1Antituberculosis 
treatment, remaining 2 patients were started on category 2 ( these 2 
patients are under early group) . In 60 patients of this study only 6 
patients had extra pulmonary tuberculosis. 2 out of 6 extra pulmonary 
Tuberculosis patients were in late group. Remaining 54 patients are 
pulmonary tuberculosis . 
 
 SPUTUM SMEAR EXAMINATION ( TABLE 8 ) 
Only 5 patients out of 54 patients with pulmonary tuberculosis had 
sputum smear positive. In extra pulmonary TB , lymphadenopathy was 
present in 2 cases, pleural effusion in 2 cases. Tuberculous meningitis & 
abdominal TB were the  remaining subjects             Even though 53 out of 
60 patients had anaemia, but less than 8 gm present only in 5 patients. 
Only one patient HAD worsened anaemia after ART. 
  
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME 
(TABLE 5) 
In  this study  only 5 patients developed immune reconstitution 
inflammatory syndrome. Of these 4 patients were in early group. One 
patient was in late group.  In this 5 patients , extra pulmonary tuberculosis 
was present in 2 subjects, pulmonary tuberculosis was present in 3 
subjects. Only 1 out of 5 patients were started on CAT-2  ATT. 
Remaining 4 were started on CAT-1 ATT. Only one patient( early ART 
group) out of 5 patients with IRIS had hepatitis due to ATT. when 
compared  early ART  group patients had no significant increase in 
incidence of IRIS than late ART group patients. Although all 60 patients 
had completed ATT ,2 subjects ( one from each group) died . There is no 
significant difference of mortality noted  in both groups. 
ADVERSE EFFECTS 
 Adverse effects of drug developed in 3 out of 60 patients.  Two 
patients developed hepatitis. One had worsened anaemia. Two of these 
were in early group, one in late group. There was no significant 
difference of adverse effects   noted in both groups. 
  
  
CD4 COUNT (TABLE 11)  
CD 4 count was done serially in every 6 months and compared in 
both groups. Mean of baseline CD4 count in early group is 170 Mean of 
baselineCD4 count in late group is 152. There is no significant difference 
of baseline CD4 count noted in both groups. Mean of 6 months CD 4 
count in early group is 211. Mean of 6 months CD 4 count in late group is 
158. There is significant difference of 6 months CD 4 count noted. P 
value  is0.016 ( less than 0.05). Mean of 12 months CD4 count in early 
group is 265 Mean of 12 months CD 4 count in late group is 174There is 
significant difference of 12 months CD4 count noted. P value is 0.001( 
less than 0.05). 
 
Although there is rise in CD4 count serially , progressive increase 
was better in early ART group than late ART group . Since CD4 count is 
marker of immune dysfunction it indicates the progression of HIV. 
 
Even though there is rise in CD4 count in both groups, but 
relatively there is increased CD4 count in early group than late group. 
HIV disease  progression was slower in early ART group than in late 
ART group. So in this study  even though there is high incidence of IRIS 
early ART group, HIV disease progression was slower in early group.  
  
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 
 
  
  
CONCLUSION 
 
Before start of study, a written/ Informed consent was obtained 
from all the patients registered for the study, applying inclusion and 
exclusion criteria. DOTS given according to RNTCP category, 
Depending on the CD4 counts and WHO clinical staging ART was 
administered to all the patients.  
 
Investigations were done initially and were repeated with each 
follow up. A specially designed proforma for each patient was made and 
the data collected likewise were transferred to a master chart. These 
results were subjected to the Statistical analysis. The study so completed 
revealed the following conclusions Our study revealed the male 
preponderance of 60% which is indicative of barriers preventing access to 
females to the ART. Grouping of patients with respect to age revealed 
that majority of subjects (43.3%) belonged to above 25-44 years age 
group which indicates that most patients affected by HIV/AIDS are in the 
sexually active group. 
  
  
 
1. Increased incidence of IRIS in early ART group than delayed 
ART group but it is not significant 
2. CD4 count was improved more in early ART group than 
delayed ART group 
3. HIV  disease progression is slower in early ART group than late 
ART group 
4. No significant difference in mortality, tuberculosis outcome, 
adverse effects  noted in among the two groups. 
5.  In this study Even though there is increased incidence of 
IRIS in early ART group compared to delayed ART group, 
early ART initiation is preferred over delayed ART in view 
of delaying  HIV disease progression. 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
LIMITATIONS   
  
LIMITATIONS 
 
1. In this study ,60 patients were taken as sample size, Sample size 
was small 
2. Quality of life ,  body mass index, disability grading, plasma  viral 
load were not considered  in this study 
3. Duration of study was short, follow up needed for longer duration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
SUMMARY 
  
  
SUMMARY 
 
1. Majority of patients were in the age group of above 40 years 
2. Out of 60 people 60% were male, 40% were female 
3. Most common form of tuberculosis was pulmonary                 
tuberculosis(90%) 
4. 8.3% were sputum smear positive 
5. 3.3% were died during study period, shares by each group 
6. 8.4% were developed IRIS, of these 6.7% in early group. 
7. CD4 count even though increased in both groups, it is improved 
more in early group than late group 
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KEY WORDS FOR MASTER CHART 
DUR     – INTERVAL BETWEEN ATT AND ART 
TB RX   – TUBERCULOSIS TREATMENT 
IRIS       - IMMUNE RECONSTITUTION INFLAMMATORY 
SYNDROME 
HB        - HAEMOGLOBULIN 
TC        - TOTAL COUNT 
ESR      - ERYTHROCYTE SEDIMENTATION RATE 
B.UREA – BLOOD UREA 
S.CREAT –SERUM CREATININE 
PUL – PULMONARY TUBERCULOSIS 
EXT.PUL – EXTRA PULMONARY TUBERCULOSIS 
INC.PLU.EFF –INCREASED PLEURAL EFFUSION 
INC.PUL.INF- INCREASED PULMONARY INFILTRATES 
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ABBREVIATIONS 
 
3TC-LAMIVUDINE 
AIDS- ACQUIRED IMMUNODEFICIENCY SYNDROME 
AFB- ACID FAST BACILLI 
ANC- ANTE NATAL CLINIC 
ART- ANTIRETROVIRAL THERAPY 
ARVS - ACUTE RETROVIRAL SYNDROME  
ATT- ANTI TUBERCULOSIS TREATMENT 
ATV/R- RITONAVIR-BOOSTED ATAZANAVIR 
 
BCG-  BACILLUS CALMETTE–GUÉRIN 
 
cART- COMBINATION ANTI RETROVIRAL THERAPY 
 
CD- CLUSTER OF DIFFERENTIATION 
CDC- CENTRE FOR DISEASE CONTROL 
CMI- CELL MEDIATED IMMUNITY 
CNS – CENTRAL NERVOUS SYSTEM 
d4T-STAVUDINE 
DC- DENDRITIC CELL 
DNA – DEOXYRIBO NUCLEIC ACID 
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DOTS – DIRECTLY OBSERVED THERAPY SHORT COURSE 
EFV- EFAVIRENZ 
EIA – ENZYME IMMUNOSORBENT ASSAY 
EPTB- EXTRA PULMONARY TUBERCULOSIS 
FDA- FOOD AND DRUG ADMINISTRATION 
FTC- EMTRICITABINE 
GIT – GASTEROINTESTINAL SYSTEM 
HAART – HIGHLY ACTIVE ANTI RETROVIRAL THERAPY 
HIV - HUMAN IMMUNODEFICIENCY VIRUS 
ICMR – INDIAN COUNCIL OF MEDICAL RESEARCH 
INC PLU- INCREASED PLEURAL EFFUSION 
INC PUL- INCREASED PULMONARY INFILTRATES 
IRIS- IMMUNE RECONSTITUTION INFLAMMATORY 
SYNDROME 
LPV/R- LOPINAVIR/RITONAVIR 
MDR TB- MULTIDRUG RESISTANT TUBERCULOSIS 
MM – MONOCYTE MACROPHAGE 
MTCT – MOTHER TO CHILD TRANSMISSION 
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NACO – NATIONAL AIDS CONTROL ORGANISATION 
NNRTI – NON NUCLEOSIDE REVERSE TRANSCRIPTASE 
INHIBITOR 
NRTI – NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR 
OI- OPPURTUNISTIC INFECTION 
PGLA- PERSISTENT GENERALISED LYMPH ADENOPATHY  
 
PI- PROTEASE INHIBITOR 
 
PLWHA- PEOPLE LIVING WITH HIV AND AIDS 
 
PTB- PULMONARY  TUBERCULOSIS 
 
RNA – RIBONUCLEIC ACID 
SAPIT – STARTING ANTIRETROVIRAL THERAPY AT THREE 
POINTS IN TUBERCULOSIS 
SIMD-STAGE OF IMMUNODEFICIENCY 
SIV – SIMIAN IMMUNODEFICIENCY VIRUS 
STD- SEXUALLY TRANSMITTED DISEASE 
TB –TUBERCULOSIS 
TDF- TENOFOVIR 
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UNAIDS- THE JOINT UNITED NATIONS PROGRAMME ON HIV 
AND AIDS 
VLPS-VIRUS LOW PRODUCTIVE SUBDUED 
VNPL- VIRUS NON- PRODUCTIVE LATENT 
WHO- WORLD HEALTH ORGANISATION 
XDR TB- EXTENSIVELY DRUG RESISTANT  TUBERCULOSIS 
 
 
 
 
 
 
 
 
 
